AI Terminal
Remedy Entertainment Oyj
Business and Financial Review • Apr 29, 2024
3288_10-q_2024-04-29_fadfd2c0-fbf9-483c-a290-8dcc3a8ac10a.pdf
Business and Financial Review
Open in ViewerOpens in native device viewer
Business review JANUARY–MARCH 2024
Remedy Entertainment Plc | Stock exchange release | April 29, 2024, at 09:00 a.m. EEST
Remedy Entertainment Plc | Business Review January–March 2024
Franchise strategy clarified by the Control publishing rights acquisition
Higher revenue and improved profitability versus the comparison period
The Business Review is unaudited. Figures in parentheses refer to the comparison period in the previous year, unless otherwise stated.
Highlights from January–March 2024
- Revenue increased by 56.2% to EUR 10.8 (6.9) million.
- EBITDA increased to EUR -1.2 (-4.9) million.
- Operating profit (EBIT) was EUR -2.1 (-5.6) million, and the operating profit margin was -19.3% (-81.0%) of revenue.
- Cash flow from operations was EUR 3.3 (-3.9) million.
- In February, Remedy acquired full rights to the Control franchise from 505 Games. Upon the transaction, all rights to Control, codename Condor, Control 2, and all future Control products reverted to Remedy.
Key Figures
| MEUR, IFRS, Group, unaudited |
1–3/2024 | 1–3/2023 | 1–12/2023 |
|---|---|---|---|
| Revenue | 10.8 | 6.9 | 33.9 |
| Growth in revenue, % | 56.2% | -45.4% | -22.2% |
| EBITDA | -1.2 | -4.9 | -17.0 |
| Operating profit (EBIT) | -2.1 | -5.6 | -28.6 |
| Operating profit, % of revenue | -19.3% | -81.0% | -84.4% |
| Result for review period | -2.0 | -5.6 | -22.7 |
| Result for review period, % of revenue |
-18.5% | -81.6% | -66.8% |
| Balance sheet total | 90.4 | 94.2 | 79.0 |
| Cash flow from operations | 3.3 | -3.9 | -16.0 |
| Net cash | 21.0 | 43.9 | 23.8 |
| Cash and cash equivalents | 17.0 | 39.8 | 20.1 |
| Net gearing, % | -31.5% | -52.3% | -35.1% |
| Equity ratio, % | 73.7% | 89.1% | 85.5% |
| Capital expenditures | 19.6* | 2.1 | 10.0 |
| Average number of personnel during review period (FTE) |
345 | 328 | 334 |
| Headcount at the end of period | 360 | 342 | 352 |
| Earnings per share, € | -0.15 | -0.42 | -1.68 |
| Earnings per share, € (diluted) | -0.14 | -0.41 | -1.66 |
| Number of shares at the end of period |
13,516,401 | 13,469,100 | 13,490,151 |
*Contains 16.9 million invested in publishing rights of Control franchise
Comments by CEO Tero Virtala
In February, we took a significant strategic step by acquiring full rights to the Control franchise from 505 Games for the maximum purchase price of approximately EUR 17 million. At the same time, we made the first of three payments, which had a 3.8 million negative impact on our cash position. The next payments are expected to take place in the latter half of 2024 and early 2025. Thanks to the Control acquisition, we can now freely decide on the future of our two established franchises, Control and Alan Wake. We are currently weighing self-publishing and related business models. Simultaneously, we are actively looking into different partner publishing models and evaluating potential partners.
In February 2024, Remedy announced that Alan Wake 2 had sold 1.3 million units as of the beginning of February. Alan Wake 2 sales have continued with a high average price. At the end of the first quarter, the game had recouped a significant part of the development and marketing expenses. During the first quarter, the team focused on working on the downloadable content (DLC) that will extend Alan Wake 2.
In the first quarter of 2024 revenue was higher compared to a year ago. Development fees increased from the comparison period, mainly due to higher development fees from Max Payne 1&2 remake. Royalties grew year-on-year driven by Control and Alan Wake Remastered. Alan Wake 2 did not yet generate royalty revenue. In the first quarter our operating profit improved compared to a year ago. The operating cash flow was positive and at the quarter end we had EUR 17.0 million in cash and cash equivalents, with an additional EUR 10.4 million invested in financial instruments.
Codename Condor, a part of the Control franchise, moved to full production meaning it has reached the final development stage before a game is launched. Based on wide internal playtests, we can see that the core loop is engaging, and the game brings a unique Remedy angle to the genre.
Control 2 team has focused on finalizing the proof-of-concept stage, in which the game world, game mechanics and visual targets are proven. We expect the project to advance to the production readiness stage during the second quarter of 2024.
Max Payne 1&2 remake continued in the production readiness stage. The game is expected to move into full production during the second quarter of 2024.
Codename Kestrel continued in the concept stage. The team works to refine the game concept.
After the Control rights acquisition, we can freely choose the right model with which to grow our two franchises and expand the Remedy Connected Universe. When expanding high-quality franchises, each new game benefits from the success of its predecessors and the existing fan base. We continue seeking further focus and synergies across our games portfolio and operations. Soon we expect to have two game projects simultaneously in full production and one in the production readiness stage for the first time. We are confident that the good progress of the beginning of the year carries over to the full production stages.
Outlook 2024 (unchanged)
Remedy expects its revenue to increase from the previous year and operating profit (EBIT) to improve.
The revenue growth rate and EBIT improvement are meaningfully dependent on the choice between self-publishing and/or choosing a new publishing partner for the games in the Control franchise (Codename Condor and Control 2).
We will specify the Outlook for 2024 when the decision for the business model and the potential agreements for Control 2 and Condor have been made.
Long-term business prospects
We have two established own franchises, Control and Alan Wake, which are linked through the Remedy Connected Universe. Growing and expanding these franchises will be a key part of our future. In addition, we work with a partner franchise Max Payne that was originally created by Remedy.
Events after the end of the reporting period
The Annual General Meeting was held on April 12, 2024. The Annual General Meeting adopted the Financial Statements for 2023, discharged the members of the Board of Directors and the CEO from liability, adopted the company's Remuneration Policy and Remuneration Report and approved all proposals made to the Annual General Meeting in the form included in the notice to the Annual General Meeting. The Annual General Meeting resolved that no dividends shall be distributed for the financial period ended on December 31, 2023. Markus Mäki, Kaisa Salakka, Sonja Ängeslevä, Henri Österlund and Kai Tavakka were elected to the Board of Directors. At its organizing meeting held after the Annual General Meeting, the Board of Directors elected Markus Mäki to continue as the Chairman of the Board of Directors.
Between January 1 and March 31, 2024, a total of 36,250 new shares of Remedy were subscribed for with the company's stock options 2018 and 2019. The shares subscribed for under the stock options were registered in the Trade Register on April 11, 2024, after which the total number of shares is 13,552,651.
On April 25, 2024, Remedy announced changes to the core management team. Remedy's Chief Operations Officer, Christopher Schmitz has resigned and will leave Remedy on May 31, 2024. Mikael Kasurinen has been appointed Remedy's Creative Director and will share the Creative Director responsibilities with Sami Järvi. Kasurinen joins Remedy's Core Management Team.
Remedy received the following flagging notifications after the reporting period. Tencent Holdings Limited's total holding increased above the 10% threshold on April 24, 2024. Working Capital Advisors (UK) Ltd's total holding decreased below the 5% threshold on April 24, 2024.
Webcast and conference call
Remedy will host a webcast and conference call in English on its Q1 2024 financial results for investors, analysts and media on April 29, 2024, at 2:00 p.m. (EEST). Remedy's financial results will be presented by CEO Tero Virtala and CFO Terhi Kauppi.
The Business review will be available after publication on Remedy's Investor website: https://investors.remedygames.com/financials-and-reports/financial-reports/.
Webcast details:
Register in advance for the webcast: https://remedy.zoom.us/webinar/register/WN\_CadK4Ci9TcOE4gL113WnnQ
After registering, you will receive a confirmation email containing information about joining the webcast.
Conference call details:
Dial in by calling your local phone number a few minutes before the briefing begins. International numbers are available at: https://remedy.zoom.us/u/kbZXDFBZgc.
Finland: +358 9 7252 2471 Sweden: +46 850 539 728 United Kingdom: +44 330 088 5830 United States: +1 646 558 8656
Webinar ID: 857 1013 9504 Passcode: 487991
A recording of the webcast will be available afterwards on Remedy's Investor website: https://investors.remedygames.com/financials-and-reports/webcasts-andpresentations/.
More information
Liisa Eloranta, Senior Investor Relations Specialist Phone: +358 50 4334 992 Email: [email protected]
Remedy in brief
Remedy Entertainment Plc is a pioneering, globally renowned video game company founded in 1995 and headquartered in Finland with an office in Stockholm, Sweden. Known for its story-driven and visually stunning action games, Remedy has created multiple successful, critically acclaimed franchises such as Control, Alan Wake and Max Payne. Remedy also develops its own Northlight game engine and tools technology that powers many of its games. Remedy's shares are listed on Nasdaq Helsinki's main list.
Notes to Business Review January–March 2024
Revenue breakdown per quarter
| EUR thousand | 1–3/2024 | 10–12/2023 | 7–9/2023 | 4–6/2023 | 1–3/2023 |
|---|---|---|---|---|---|
| Development fees | 8,961 | 7,648 | 6,714 | 7,948 | 6,440 |
| Royalties | 1,834 | 2,655 | 1,102 | 955 | 471 |
| Total | 10,795 | 10,302 | 7,816 | 8,903 | 6,911 |
Calculation formulas used for the indicators
EBITDA: Operating profit (EBIT) + depreciation and amortization Operating profit (EBIT): Profit (loss) before taxes and financial items Operating profit, % of revenue: Operating profit (EBIT) / revenue Net cash: Cash and cash equivalents + liquid investments* - interest-bearing liabilities Net gearing, %: (Interest-bearing liabilities - cash and cash equivalents – liquid investments*) / shareholders' equity Equity ratio: Shareholders' equity / (balance sheet total - advances received) Capital Expenditures: Change in tangible and intangible assets added by depreciation of these assets
*Liquid investments include Remedy's liquid investments to equity funds.
Espoo, April 29, 2024 Remedy Entertainment Plc Board of Directors
This is not an interim report as defined in IAS 34. Remedy follows the half-year reporting schedule according to Finnish Securities Market Act and publishes business reviews off the first three and nine months of the fiscal year. These business reviews will include the most essential information regarding the company's financial performance. The financial figures presented in this business review are unaudited.